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The role of amyloid-b (Ab) neuropathology and its significant changes in biofluids after traumatic brain
injury (TBI) is still debated. We used ultrasensitive digital ELISA approach to assess amyloid-b1-42 (Ab42)
concentrations and time-course in cerebrospinal fluid (CSF) and in plasma of patients with severe TBI and
investigated their relationship to injury characteristics, neurological status and clinical outcome. We found
decreased CSF Ab42 levels in TBI patients acutely after injury with lower levels in patients who died 6
months post-injury than in survivors. Conversely, plasma Ab42 levels were significantly increased in TBI
with lower levels in patients who survived. A trend analysis showed that both CSF and plasma Ab42 levels
strongly correlated with mortality. A positive correlation between changes in CSF Ab42 concentrations and
neurological status as assessed by Glasgow Coma Scale (GCS) was identified. Our results suggest that
determination of Ab42may be valuable to obtain prognostic information in patients with severe TBI as well
as in monitoring the response of the brain to injury.
S
tudies in Alzheimer disease (AD) have highlighted the utility of CSF amyloid-b peptide (Ab) as a ‘state
marker’ of the disease, reliably reflecting AD pathology1,2. Recently, an increasing body of literature has
shown potential links between traumatic brain injury (TBI) and forms of neurodegeneration such as
Alzheimer disease3–5. Recent studies have also shown significant changes in brain extracellular amyloid-b
dynamics in patients with severe brain injury, either in fluids or tissue6–8. The 42–amino acid form of amy-
loid-b1–42 (Ab42) is of special interest; this form appears to have the greatest propensity to deposit into insoluble
plaques, one of the pathological hallmarks of Alzheimer’s disease, as well as to aggregate into oligomeric Ab
species and is deemed to underlie the neurodegeneration/neurotoxicity observed in AD in combination with
other molecular targets and biomarkers such as tau9. In this study we have used a novel ultrasensitive digital
ELISA (Single Molecule Arrays, SiMoA) to assess amyloid-b1-42 (Ab42) concentrations in CSF and matching
plasma samples of patients with severe traumatic brain injury (TBI) and correlated results with injury character-
istics, neurological status and clinical outcome. The developed ELISA for Ab42 has been analytically qualified and
validated and shows no matrix interference and good precision and accuracy.
Results
Study population. A total of 12 patients with severe TBI and 20 controls were included for analyses. The clinical
and demographic characteristics of the patients are summarized in Table 1. Patients with severe TBI had similar
percentage of diffuse injury and focal mass lesion as well as survival/mortality rate (Table 1). In the control
population (n 5 20), 100% were men, and the average age was 26 6 4 years. Except for the age (p 5 0.001), there
were no significant differences in the characteristics between control subjects and TBI patients.
CSF and plasma concentrations of Ab42 acutely after injury. The median CSF and plasma concentrations of
Ab42 acutely after injury for patients with severe TBI and for controls are shown in Table 2. Ab42 concentrations
OPEN
SUBJECT AREAS:
BIOMARKERS
MEDICAL RESEARCH
Received
14 May 2014
Accepted
28 August 2014
Published
10 October 2014
Correspondence and
requests for materials
should be addressed to
S.M. (stm_mondello@
hotmail.com;
smondello@unime.it)
SCIENTIFIC REPORTS | 4 : 6446 | DOI: 10.1038/srep06446 1
in CSF were significantly lower in TBI patients than in controls (p,
0.0001); in contrast, plasma concentrations of Ab42 were significantly
lower in controls than in TBI patients (p , 0.0001) (Table 2, Fig. 1).
CSF and plasma levels of Ab42 did not correlate with age, time to
sample withdrawal and severity of injury as assessed by GCS and
motor GCS. There was no correlation between CSF and plasma
levels of Ab42 (Spearman correlation coefficients 5 20.02, p 5
0.946). CSF and plasma Ab42 concentrations did not differ between
patients with diffuse injury and focal mass lesion (p 5 0.93 and p 5
0.49, respectively). CSF Ab42 concentrations were lower in patients
who died compared to patients who survived; conversely, plasma
concentrations were lower in survivors than non-survivors
(Table 2). CSF Ab42 significantly decreased from normal through
TBI survivors to TBI non-survivors (P for trend 5 p , 0.0001;
Jonckheere-Terpstra test), while plasma Ab42 significantly
increased from normal through TBI survivors to TBI non-survivors
(P for trend 5 p , 0.0001; Jonckheere-Terpstra test) (Fig. 2).
Description of Longitudinal CSF and plasma Ab42 Levels. CSF
Ab42 levels were decreased in TBI patients compared with
controls over the study period (Fig. 3). CSF Ab42 concentrations
were significantly lower on day 1 and 3 and from day 5 to day 7
(Fig. 3). CSF Ab42 nadir level was on day 6 after injury (62.62 pg/mL
[42.73–233.4]). Figure 3B shows daily plasma Ab42 concentrations
that, in contrast, were significantly and persistently elevated in TBI
subjects compared to controls. Plasma Ab42 levels peaked 6 days
after injury (25.03 pg/mL [16.01–31.11]). Within-subjects compari-
son in the temporal analysis window showed that CSF and plasma
Ab42 levels did not vary significantly over the study period (p 5 0.09
and p 5 0.55, respectively, Friedman test). Plasma Ab42 concen-
trations did not correlate with CSFAb42 concentrations at any of the
time points examined.
CSF Ab42 Levels in Relation to Neurological Status. In several
patients, CSF Ab42 was associated with the global neurological
status, as assessed with the Glasgow Coma Score (GCS); higher con-
centrations of CSF Ab42 were associated with patient neurological
status improvement, whereas reduced Ab42 levels correlated with
patient deterioration/worsening. CSF Ab42 changes appeared to
track, and in some cases even precede neurological status changes
(Fig. 4).
Discussion
In this investigation, we assessed and monitored CSF and plasma
Ab42 values in matched longitudinal samples of patients with severe
TBI using the SiMoA Ab42 assay. This breakthrough technology
allowed highly sensitive and precise quantification of Ab42, improv-
ing overall diagnostic accuracy, in a small but clinically well-char-
acterized TBI cohort.
We found that initial Ab42 levels presented opposite dynamics in
CSF and plasma of patients with severe TBI, with significant reduc-
tions in CSF Ab42 concentrations and increases in plasma Ab42
levels early after injury compared to controls. The reduction of
CSF Ab42 concentrations in TBI patients might suggest deposition
of aggregated Ab42 and plaque formation10 in the brain early after
injury, as reported in previous neuropathological studies10,11.
Nonetheless, it might also result from Ab42 leakage across an
impaired blood-brain barrier (BBB) into the blood. This later hypo-
thesis is supported by a substantial rise of Ab42 in plasma.
Interestingly, TBI patients who died were characterized by more
marked decrease in CSF Ab42 and highly elevated levels of plasma
Ab42 compared to controls, while CSF and plasma Ab42 values in
survivors were intermediate between these 2 groups (Fig. 2). This
suggests that themagnitude of both CSF reduction and plasma eleva-
tion in Ab42 increases with increasing brain injury severity. These
findings may be explained by the fact that severely injured patients
doomed to die had a more extensive BBB damage/breakdown and
consequently higher Ab42 levels entering the peripheral circulation
as compared to individuals with mild injures. Supporting these
observations, substantial evidence has now accumulated showing
the direct influence of BBB disruption on the clinical outcome after
TBI12. A sensitivemarker that can predict outcome, and capture TBI-
Table 1 | Summary of Demographic and Clinical Data for Severe
Traumatic Brain Injury cases included in the study
sTBI (n 5 12)
Age, years, mean (SD) 49 (17.6)
F/M, n (%) 1/11 (8/92)
GCS, median (range)* 7 (3–8)
Time to first sample withdrawal, h, median (range) 15 (5–24)
Mechanism of injury, n (%)
Motor vehicle 4 (33)
Motor cycle 1 (8)
Fall 5 (42)
Other 2 (17)
CT classification, n (%)*
Diffuse injury 6 (50)
I -
II 5 (42)
III -
IV 1 (8)
Focal Mass Lesion 6 (50)
V 1 (8)
VI 5 (42)
Outcome GOSE 6 mo, n (%)
Poor outcome 6 (50)
1 6 (50)
Good outcome 6 (50)
5 2 (17)
7 1 (8)
8 3 (25)
Abbreviations: GCS 5 Glasgow Coma Scale; CT 5 Computed Tomography; GOSE 5 Glasgow
Outcome Score Extended.
*At the time of admission.
Table 2 | CSF and plasmaAb42 levels in patients with severe TBI acutely after injury and in controls. Data are given asmedian (interquartile
range)
N CSF Ab42 (pg/mL) N Plasma Ab42 (pg/mL)
TBI Admission 12 105.9 (46.02–216.2){ 12 17.02 (14.75–28.59){
Diffuse Injury (Admission) 6 105.9 (52.45–227.6) 6 19.65 (14.91–32.90)
Focal Mass Lesion (Admission) 6 118.7(16.59–239.3) 6 16.61 (13.21–27.35)
Survivors (Admission) 6 161.1 (65.67–286.9)u 6 16.29 (14.13–18.88)u
Non-Survivors (Admission) 6 46.02 (11.55–172.4){ 6 27.97 (13.66–32.90){
Controls 15 537.6 (350.8–710.0) 20 7.289 (6.126–8.668)
{p , .0001 (p values of the Mann-Whitney test for differences between the groups [TBI versus Controls]).
up , .05, or { p , .0001 (p values of the post-hoc test for differences between Survivors and Non-survivors versus Controls).
www.nature.com/scientificreports
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induced BBB disruption could be extremely useful; further studies
assessing the relationships between TBI, BBB disruption and levels of
Ab42 are warranted.
Overall, our findings complement and extend previous results on
the topic of amyloid peptides in biofluids following TBI13.
Consistently with our observations, several studies have shown
decreased CSF Ab42 concentrations after TBI14,15 and an association
with poor clinical outcome14. On the other hand, in a study byOlsson
and colleagues16, marked increase in ventricular CSF Ab42 and
unchanged level of plasma Ab42 were observed in patients after
severe TBI. However, this discrepancy may be due to different col-
lection protocols, lack of control group, patient characteristics and
outcome, or different determination techniques. In particular, in our
study the ultrasensitive digital immunoassay for quantification of the
Ab42 in plasma enables measurement of this marker at concentra-
tions not reliably detected with prior generations of commercial
assay andmight explain the conflicting results with the earlier report.
Within this study, we did not found differences between the Ab
levels in patients with diffuse brain injury compared with focal TBI.
This finding stands in contrast to previous microdialysis (MD) stud-
ies, which found increased interstitial fluid (ISF) Ab42 levels in
patients who sustained diffuse brain injury8,17. However, MD data
are not directly comparable to CSF and plasma owing to the fact that
interstitial fluid comes from a relatively restricted area of the brain
and its composition depends on the microdialysis catheter location.
An alternative explanation is that CT and the broad distinction
between focal TBI and diffuse axonal injury (DAI) based on the
Marshall classification18 may underestimate the extent of compo-
nents of axonal injury in patients with predominately focal TBI19.
Advanced neuroradiological tools such as MRI and ideally diffusion
tensor imaging (DTI) could be appropriate approach to solve this
question.
In line with previous investigations in patients with mild cognitive
impairment or AD20,21, no significant correlation between the levels
of Ab42 in CSF and plasma was identified in our study. These find-
ingsmight indicate a delayed release ofAb42 into the blood after TBI.
However, the relation between brain ISFAb CSFAb42 and plasma
Ab42 is fairly complex21 possibly involving BBB, paravascular path-
ways and astrocytic water transport (aquaporin4-dependent bulk
flow). However, the role of such structures in the clearance of bio-
markers has only recently been explored22 and will be a critical area
for future investigation.
The longitudinal study showed persistent reduced levels of CSF
Ab42 and elevated levels of plasma Ab42 over time suggesting that
levels of this marker reflect and characterize pathophysiological pro-
cesses that start with the primary injury, evolve over the acute period
Figure 1 | CSF and plasma Ab42 concentrations acutely after injury in patients and controls. Ab42 concentrations acutely after injury (24 hrs) in CSF
(A) and in plasma (B) of patients with severe TBI and controls. The horizontal line in each box represents the median and the boxes representing 25th to
75th quartile. Significant differences are indicated with *** (P , 0.0001) (Mann–Whitney U-test).
Figure 2 | Box-and-whisker plots demonstrating median CSF (A) and plasma (B) Ab42 concentrations acutely after injury in TBI patients who
died and in TBI patients who survived, and in controls. Jonckheere-Terpstra test demonstrates an increase in CSF (A) Ab42 in patients across the groups
and a decrease in plasma (B) Ab42 in patients across the groups. The black horizontal line in each box represents themedian, with the boxes representing
the interquartile range.
www.nature.com/scientificreports
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and encompass the subacute and chronic phases. It is of note that, the
pattern of changes in CSF levels of this protein observed over time
correlated with neurological outcome, as reported by others6.
Our study has several limitations. First, it consists of a relatively
small sample size that did not allow multivariate analyses including
significant clinical and demographic variables. Second, Ab is pro-
duced by many different cells in the body20,23, therefore, increased
release of Ab42 from extracerebral origin cannot be excluded.
Nonetheless, the exclusion of multiple injuries makes it likely that
the changes in plasma levels of this marker fundamentally reflect the
brain injury and associated BBB disruption. Third, there was a sig-
nificant age difference between TBI patients and controls. However,
we did not find any significant correlation between age and Ab42
concentrations in CSF and plasma. In addition, the prognostic value
of Ab42 levels was unrelated to age. Furthermore, these findings are
in agreement with those of 2 recent studies demonstrating a dia-
gnostic and prognostic value of the Ab42 levels in patients with acute
and chronic intracerebral hemorrhage that was independent of
age24,25. Finally, in future studies it might be worthwhile to analyze
the influence of other relevant clinical variables, such as polytrauma,
renal function and APOE e4 status, on plasma Ab42 concentrations.
In conclusion, our data show an opposite dynamics of Ab42 in
CSF and plasma and a stepwise decrease and increase in CSF and
plasma Ab42 concentrations, respectively, occurring with increasing
severity of injury. Importantly, our work indicates for the first time a
potential clinical relevance in TBI of plasma Ab42 as detected by
novel ultrasensitive digital immunoassay. Future studies that include
a larger sample size will be required to validate these findings and to
determine whether combined information fromCSF and plasma b42
levels might be effective predictors of outcome and BBB disruption
after severe TBI.
Methods
Patients. This study is part of the BANDITS (Biomarker Assessment for
Neurotrauma Diagnosis and Improved Triage System) Feasibility Study, an
observational study on the association between brain damage markers and
demographic and clinical variables, neuroimaging, and clinical outcome of patients
with severe TBI. Other biomarker analyses from this project have previously been
reported elsewhere26,27. In the current studywe focused on a pilot cohort of 12 patients
in whom paired CSF and plasma samples were available. Severe traumatic brain
injury was defined as a Glasgow Coma Score (GCS) of 8 or less on the hospital
admission. Exclusion criteria were no informed consent, age , 18 years, known
history of neurological and/or autoimmune disease, multiple injuries and pregnancy.
All patients underwent insertion of an intracranial pressure (ICP) monitor using a
ventriculostomy catheter that was placed as part of the routine medical care for
patients with severe TBI. The study protocol was approved by the local ethics
committee of the two sites involved (Pecs, Szeged) and by the Western Institutional
Review Board (WIRB) and Human Research Protection Office (HRPO). Next of kin
or legal representatives provided written informed consent for study participation.
Figure 3 | Longitudinal CSF and plasmaAb42 Levels in TBI patients and controls.The concentration of CSFAb42 (A)was significantly decreased in TBI
patients on day 1 and 3 and from day 5 to day 7 after injury compared to controls. Plasma Ab42 (B) was significantly elevated over the study period,
compared to controls. The horizontal bar represents median concentration. Significant differences are indicated with * (P, 0.05), ** (P, 0.01) or ***
(P , 0.001) (p values of the post-hoc Dunn’s Test for differences between the groups [TBI versus Controls]).
www.nature.com/scientificreports
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The study was conducted in accordance with the approved guidelines and
regulations, in line with the tenets of the Declaration of Helsinki.
Initial computed tomography (CT) scans obtained on admission were classified
according to the classification of Marshall et al. For the purpose of our analysis,
Marshall score was further categorized into two groups (diffuse injury versus focal
mass lesion), as previously described28. Outcomewas assessed at 6months post-injury
using the Glasgow Outcome Score Extended (GOSE). Patient characteristics are
shown in Table 1.
Because there are no certified reference standards for Ab42 and values vary
depending on the assay used, we included a control population consisting of 20
individuals who underwent lumbar puncture (LP) to exclude possible peripheral
nervous system disorders, suspicion of subarachnoid hemorrhage or meningitis and
with proven negative results. Exclusion criteria were antecedents of neurologic dis-
ease and any contraindication for lumbar puncture.
Sample Collection and Handling. In patients with severe TBI, CSF for biomarker
analysis was collected on admission after the insertion of an intracranial pressure
monitoring device (median 12.5 hrs, range 5–24 hrs) and daily up to 7 days. In
control subjects CSF was collected by LP. Blood and CSF samples were drawn at the
same time. Approximately 4–5 mL of CSF and plasma were collected from each
subject at each sample point. The samples were immediately centrifuged for 10 min at
4000 rpm, frozen and stored at 280uC until assayed.
Measurement of Ab42. Quantification of CSF and plasma Ab42concentrations was
performed at Quanterix Corporation, Cambridge, Massachusetts, USA. All samples
were blinded to case identity and assayed in triplicate. Samples from individual
patients were tested within a single plate. Ab42 was measured using SiMoA
technology. This method involves performing a paramagnetic bead–based ELISA,
followed by isolation of individual capture beads in arrays of femtoliter-sized reaction
wells29. Singulation of capture beads withinmicrowells permits buildup of fluorescent
product from an enzyme label, so that signal from a single immunocomplex can be
readily detected with a CCD camera. At very low Ab42 concentrations, Poisson
statistics predict that bead containing microwells in the array will contain either a
single labeled Ab42 molecule or no Ab42 molecules, resulting in a digital signal of
either ‘‘active’’ or ‘‘inactive’’ wells. At higher Ab42 concentrations, when all wells
become occupied by at least 1 labeledAb42molecule, digitalmeasurements transition
to non-digital (analog) measurements of total fluorescence intensity. With single
molecule sensitivity, concentrations of labeling reagents can be lowered, resulting in
reduced nonspecific background. This effect enables high signal- to-background
ratios at extremely low analyte concentrations.
Arrays of femtoliter-volume wells were prepared as described. In brief, the ends of
bundles of 50,000 optical fibers were polished with diamond lapping films and etched
one end of each bundle inmild acid solution. Differential etch rates of the optical fiber
core and cladding glass of the bundles causes 4.5 mm–diameter, 3.5 mm–deepwells to
be formed, giving an array of 50 000microwells across the bundle. Optical fiber arrays
weremounted in linear groups of 8 within glass holders for bead loading and imaging,
to correspond with microtiter plate columns of 8 wells, which were used as rinse
troughs. Paramagnetic capture beads were comprised of a monoclonal anti-Ab42
antibody (Covance, 6E10) directed to the N-terminus. Biotinylated detector reagent
was comprised of a monoclonal anti Ab42 antibody (Invitrogen H31L21) directed to
the C-terminus. Streptavidin: b-galactosidase (SbG) was prepared by covalent con-
jugation of purified streptavidin (Thermo Scientific) and bG (Sigma) using standard
coupling chemistry. Bead-sample incubations and labeling of immunocomplexes in
conical 96 well plates (Axygen) were conducted. The assay was performed in three
steps, starting with analyte capture, incubation with biotinylated detector, and
labeling of the immunocomplexes with SbG. Following assay and bead collectionwith
a magnet, beads were loaded onto the arrays for imaging in a loading buffer com-
prised of PBS and 0.01% Tween-20, MgCl2, and sucrose. Wells containing beads with
labeled Ab42 were visualized by the hydrolysis of enzyme substrate (resorufin b-D-
galactopyranoside, RGP, Invitrogen) by bG into fluorescent product. RGP was
introduced to the wells during sealing of the arrays with a silicon gasket. Enzyme-
containing wells were imaged by fluorescence microscope fitted with a CCD camera.
The images were analyzed to determine the average number of label enzymes/bead
(AEB) as described. At ,70% active beads relative to total beads (low Ab42), the
signal output is a count of active beads corrected for a low statistical probability of
multiple enzymes/bead. At .70% active beads (higher Ab42), the probability of
multiple enzymes/bead increases, and average fluorescence of thewells is converted to
AEB based on the average intensities of wells containing single enzymes determined
at lower concentrations.
The assay was calibrated with Ab42 obtained from Covance and a stock solution
prepared by dilution to 3.5 ng/mL in PBS/Tween-20. Assay calibrators and controls
were prepared by dilution of the stock solution in PBS diluent containing a surfactant
and BSA (PBS/BSA). Calibrators were prepared by serial 3-fold dilution to give a
calibration range of 0–250 pg/mL. Limits of detection (LoD) were estimated as three
standard deviations above the zero calibrator across calibration curves on six separate
days (n 5 3 replicates per curve). LoDs ranged from 0.014 to 0.032 pg/mL, with an
average of 0.020 pg/mL. The limit of quantification (LoQ) was estimated to be
0.038 pg/mL from repeated measurement of immunodepleted plasma, as previously
described30. Assay imprecision was estimated at low levels of Ab42 as total coefficients
of variation (CV) from six days of repeated testing of three plasma samples. CVs
ranged from 6.1 to 10.0% at Ab42 concentrations of 0.5 to 4.8 pg/mL. Specificity for
Ab42 was evaluated by assaying 0.5, 1.0, 5.0, 10 and 50 pg/mL of the peptide variants
Ab38, Ab40, and Ab43 in PBS/BSA (Merck). No detectable cross reactivity was noted
Figure 4 | CSF Ab42 levels and neurological status. Graph showing the time course of CSF Ab42 concentrations and changes in neurological status, as
reflected by GCS, in 2 severely brain injured patients (FML, Focal Mass Lesion; DI, Diffuse Injury).
www.nature.com/scientificreports
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for the shorter Ab38 and Ab40 peptides, while the longer Ab43 variant exhibited a
cross reactivity of 11–16%. Linearity of the assay has been described previously30.
Statistical analyses. Statistical analyses were carried out using the SPSS 20.0 software
package (SPSS Inc, Chicago, Illinois, USA) and JMP version 10.0 (SAS Institute, Inc,
Cary, NC). Data normality was assessed. For descriptive analyses, continuous
variables are presented as median and interquartile range; differences were tested
using the Mann–Whitney U test. Distributions of categorical variables are presented
as frequencies and percentages. The significance of differences in proportions was
assessed using chi-square or Fisher’s exact test where appropriate. To test for
significant trends in biomarker concentrations across groups, the Jonckheere-
Terpstra test for non-parametric trend analysis was used. When trends were
significant (p , 0.05), pairwise between-group comparisons was applied (post-hoc
Wilcoxon signed-rank test). The statistical significance of within-subject longitudinal
change in CSF and plasma Ab42 concentration was analyzed using the non-
parametric Friedman test followed by post-hoc comparisons applying Dunn’s test.
The relation between quantitative variables was assessed by bivariate correlations
(Spearman rank correlation test). All statistical tests were two-tailed. P values less
than 0.05 were considered significant.
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